Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Lung Neoplasms 29Triple Negative Breast Neoplasms 13Breast Neoplasms 13Ovarian Neoplasms 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Neoplasms 10Fallopian Tube Neoplasms 10Neoplasm Metastasis 8Colorectal Neoplasms 5Adenocarcinoma of Lung 5Carcinoma 4Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lung Diseases 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thoracic Neoplasms 2Sarcoma 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Rectal Neoplasms 2Prostatic Neoplasms 2Pathologic Complete Response 2Non-squamous Non-small Cell Lung Cancer 2

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Carboplatin × 30 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡